207940.KS SAMSUNG BIOLOGICS | KR7207940008
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 6.332.750.000.000 | 5.460.315.900.000 | 15.98% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | 48.583,95 | 40.917,64 | 18.74% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 20 | 19 | 5.26% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |